ArticleFrontiers in microbiology2025
Expression and significance of INTS10 and IRF3 in chronic hepatitis B patients.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatitis B virus (HBV) infection continues to pose a significant global health challenge, affecting millions of individuals worldwide. Persistent HBV infection is acknowledged as a complex and polygenic process influenced by virological, environmental, and host genetic factors. Previous in vitro studies have indicated that INTS10 inhibits HBV replication in a manner dependent on interferon regulatory factor 3 (IRF3). Nevertheless, the relationships among INTS10 expression, IRF3, and HBV replication in patients with chronic hepatitis B (CHB) have not been comprehensively examined. Thus, this study aimed to investigate the associations between INTS10, IRF3, and HBV replication in CHB patients. Methods: A total of 127 treatment-naïve CHB patients were recruited and categorized into hepatitis B e antigen (HBeAg)-negative and HBeAg-positive groups. Quantitative PCR was utilized to quantify INTS10 and IRF3 expression levels, alongside serum HBV DNA load and conventional liver biochemical parameters, to evaluate HBV infection status. Results: Our findings revealed significantly lower expression levels of both INTS10 and IRF3 in HBeAg-positive patients compared to their HBeAg-negative counterparts. Additionally, a positive correlation was observed between IRF3 and INTS10 expression. In HBeAg-positive CHB patients, INTS10 and IRF3 levels exhibited negative correlations with HBV DNA, HBeAg, hepatitis B surface antigen (HBsAg), and total bile acid (TBA) levels. Conversely, no significant correlations were detected between INTS10 or IRF3 and these virological and biochemical markers in HBeAg-negative patients. Discussion: These results suggest that the relationship between INTS10 and IRF3 expression may be modulated by HBeAg status. This implies a potential involvement of HBeAg in the antiviral mechanisms mediated by INTS10 and IRF3 in CHB. Consequently, our study offers valuable insights that may contribute to enhanced clinical management of HBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.